[go: up one dir, main page]

PL3811931T3 - Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej - Google Patents

Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej

Info

Publication number
PL3811931T3
PL3811931T3 PL19823228.2T PL19823228T PL3811931T3 PL 3811931 T3 PL3811931 T3 PL 3811931T3 PL 19823228 T PL19823228 T PL 19823228T PL 3811931 T3 PL3811931 T3 PL 3811931T3
Authority
PL
Poland
Prior art keywords
immune checkpoint
checkpoint inhibitor
liposome composition
containing liposome
medication containing
Prior art date
Application number
PL19823228.2T
Other languages
English (en)
Inventor
Susumu Shimoyama
Tadaaki Ioroi
Mikinaga Mori
Tamami Higuchi
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of PL3811931T3 publication Critical patent/PL3811931T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19823228.2T 2018-06-20 2019-06-20 Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej PL3811931T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018116707 2018-06-20
JP2018211291 2018-11-09
PCT/JP2019/024500 WO2019244979A1 (ja) 2018-06-20 2019-06-20 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬

Publications (1)

Publication Number Publication Date
PL3811931T3 true PL3811931T3 (pl) 2024-11-18

Family

ID=68982622

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19823228.2T PL3811931T3 (pl) 2018-06-20 2019-06-20 Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej

Country Status (10)

Country Link
US (1) US12370186B2 (pl)
EP (1) EP3811931B1 (pl)
JP (1) JP7036919B2 (pl)
CN (1) CN112312895B (pl)
DK (1) DK3811931T3 (pl)
ES (1) ES2984148T3 (pl)
FI (1) FI3811931T3 (pl)
PL (1) PL3811931T3 (pl)
TW (1) TWI878230B (pl)
WO (1) WO2019244979A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763734A (zh) 2017-03-31 2023-09-19 富士胶片株式会社 脂质体组合物的制造方法
CN112789032A (zh) 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药
EP4467129A4 (en) * 2022-03-31 2025-10-29 Eisai R&D Man Co Ltd LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME
JPWO2024111564A1 (pl) 2022-11-21 2024-05-30

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7102648B1 (en) * 2000-04-11 2006-09-05 Rah Color Technologies Llc Methods and apparatus for calibrating a color display
AU7038501A (en) 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
US20080075762A1 (en) 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20070231379A1 (en) 2002-08-29 2007-10-04 Slater James L Liposome-entrapped topoisomerase inhibitors
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
US6920642B2 (en) * 2003-12-03 2005-07-26 Bart Dickens Necktie knot simulator
RU2424792C2 (ru) * 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
CA2566559C (en) 2004-05-17 2014-05-06 Inex Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
EP1809246B1 (en) 2004-10-08 2008-07-16 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
AU2005304914B2 (en) 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US20070088414A1 (en) 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
US20080206139A1 (en) 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US20110159080A1 (en) 2008-06-03 2011-06-30 Colin Lowery Composition comprising liposome-entrapped doxorubicin and methods of administration
AR076634A1 (es) 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
US11357728B2 (en) 2009-10-26 2022-06-14 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
RU2577683C2 (ru) 2010-12-27 2016-03-20 Терумо Кабусики Кайся Липосомная композиция и способ ее получения
CA2853316C (en) * 2011-10-25 2018-11-27 The University Of British Columbia Limit size lipid nanoparticles and related methods
CN102764234A (zh) 2012-08-03 2012-11-07 上海现代药物制剂工程研究中心有限公司 一种盐酸拓扑替康靶向脂质体制剂及其制备方法
EP2908909A1 (en) 2012-10-19 2015-08-26 The Regents Of The University Of California Treating tumors of the central nervous system
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN104771361B (zh) 2014-01-14 2018-06-01 中国科学院上海药物研究所 一种盐酸拓扑替康脂质体纳米制剂及其制备方法
WO2015153805A2 (en) * 2014-04-01 2015-10-08 Children's Hospital Los Angeles Targeted polymerized nanoparticles for cancer treatment
EA201790737A1 (ru) * 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
JP6316182B2 (ja) 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2017079303A1 (en) * 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
ES2869283T3 (es) 2015-11-02 2021-10-25 Fujifilm Corp Agente terapéutico antitumoral que contiene composición de liposoma de gemcitabina y kit
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
CN110114068A (zh) 2016-12-26 2019-08-09 富士胶片株式会社 脂质粒子组合物及医药组合物
CN116763734A (zh) 2017-03-31 2023-09-19 富士胶片株式会社 脂质体组合物的制造方法
CN112789032A (zh) 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药

Also Published As

Publication number Publication date
TW202015658A (zh) 2020-05-01
CN112312895A (zh) 2021-02-02
JPWO2019244979A1 (ja) 2021-06-03
JP7036919B2 (ja) 2022-03-15
EP3811931A1 (en) 2021-04-28
CN112312895B (zh) 2023-05-09
DK3811931T3 (da) 2024-09-30
US12370186B2 (en) 2025-07-29
EP3811931A4 (en) 2021-08-04
ES2984148T3 (es) 2024-10-29
FI3811931T3 (fi) 2024-09-12
EP3811931B1 (en) 2024-07-03
US20210100791A1 (en) 2021-04-08
WO2019244979A1 (ja) 2019-12-26
TWI878230B (zh) 2025-04-01

Similar Documents

Publication Publication Date Title
IL323780A (en) d-Homoperganane compounds and pharmaceutical preparation containing them
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
LT3603620T (lt) Liposomų kompozicija ir farmacinė kompozicija
ZA201801747B (en) Medication packaging and dose regimen system
PL3811931T3 (pl) Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
ZA201705591B (en) Medication packaging and dose regimen system
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
IL281073A (en) History of imidazopyridine and pharmaceutical preparations containing them
GB2578093B (en) Liquid pharmaceutical composition comprising RPL554 and HFA-134A
EP3275453A4 (en) Pharmaceutical composition containing silybin and ve
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
EP3330379A4 (en) Aptamer against insulin receptor and pharmaceutical composition containing the same
ZA201905763B (en) Liposomal compositions and solid oral dosage forms comprising the same
IL278517A (en) Azabenzaimidazole compounds and pharmaceutical preparations
EP3431126A4 (en) SPRAY ARRANGEMENT, SPRAY ARRANGEMENT PACK AND PRE-FILLED SYRINGE
GB201819957D0 (en) Novel quinazolinone derivatives inhibiting piek and pharmaceutical composition containing same
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
PL3525769T3 (pl) Tabletka ulegająca rozpadowi w jamie ustnej zawierająca burlulipazę i wytworzona z niej kompozycja farmaceutyczna
IL267775A (en) Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs
ZA202106721B (en) Pharmaceutical composition containing antibody against il-5 and use thereof
PL3811949T3 (pl) Lek kombinowany zawierający kompozycję liposomową z kapsułkowaną gemcytabiną i blokadę punktu kontroli immunologicznej
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
EP3347022A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DUTASTERIDE AND FORMULATION IN CAPSULE COMPRISING SAME